SynthesisPloS one2016
Are Urinary Tubular Injury Markers Useful in Chronic Kidney Disease? A Systematic Review and Meta Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Pooled it
- Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV-Risk Study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss.Journal of the American Society of Nephrology : JASN · 2018Trial
- Association of Thoracic Aortic Calcification with All-Cause Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study.Current medical science · 2026Article
- Urinary DKK3 as a predictor of CKD stages in reflux nephropathy in children.Turkish journal of medical sciences · 2026Article
- Non-invasive assessment techniques for renal fibrosis: advances and perspectives.Renal failure · 2025Review
- Cardiometabolic Biomarkers and Prediction of Kidney Disease Progression: The eGFR Cohort Study.Canadian journal of kidney health and disease · 2025Article
- Association of urinary excretion rates of uric acid with biomarkers of kidney injury in patients with advanced chronic kidney disease.PloS one · 2024Article
- External Validation of a Urinary Biomarker Risk Score for the Prediction of Steroid Responsiveness in Adults With Nephrotic Syndrome.Kidney international reports · 2023Article
- The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL).International journal of molecular sciences · 2023Review
- Kidney Injury Biomarkers in Leptospirosis.Revista da Sociedade Brasileira de Medicina Tropical · 2023Review
- Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.International journal of molecular sciences · 2022Review
- Evaluation of Radiographic Contrast-Induced Nephropathy by Functional Diffusion Weighted Imaging.Journal of clinical medicine · 2021Article
- A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies.Toxicologic pathology · 2021Review
- Kidney Injury Molecule 1 (KIM-1): a Multifunctional Glycoprotein and Biological Marker (Review).Sovremennye tekhnologii v meditsine · 2021Review
- Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) for Prediction of Persistent AKI and Major Adverse Kidney Events.Scientific reports · 2020Article
- Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.American journal of nephrology · 2019Article
- Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease.Advances in chronic kidney disease · 2018Review
- Analytical validation of Gentian NGAL particle-enhanced enhanced turbidimetric immunoassay (PETIA).Practical laboratory medicine · 2017Article
- Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdverse outcome of chronic kidney disease, such as end stage renal disease, is a significant burden on personal health and healthcare costs. Urinary tubular injury markers, such as NGAL, KIM-1 and NAG, could provide useful prognostic value for the early identification of high-risk patients. However, discrepancies between recent large prospective studies have resulted in controversy regarding the potential clinical value of these markers. Therefore, we conducted the first meta-analysis to provide a more persuasive argument to this debate.
methodsIn the current meta-analysis, based on ten prospective studies involving 29366 participants, we evaluated the role of urinary tubular injury markers (NGAL, KIM-1 and NAG) in predicting clinical outcomes including CKD stage 3, end stage renal disease and mortality. The prognostic values of these biomarkers were estimated using relative risks and 95% confidence interval in adjusted models. All risk estimates were normalized to those of 1 standard deviation increase in log-scale concentrations to minimize heterogeneity. Fixed-effects models were adopted to combine risk estimates. The quality of the research and between-study heterogeneity were evaluated. The level of research evidence was identified according to the GRADE profiler.
resultsuNGAL was identified as an independent risk predictor of ESRD (pooled adjusted relative risk: 1.40[1.21 to 1.61], p<0.001) and of overall mortality (pooled adjusted relative risk: 1.10[1.03 to 1.18], p = 0.001) in patients with chronic kidney disease. A borderline significance of uKIM-1 in predicting CKD stage 3 independently in the community-based population was observed (pooled adjusted relative risk: 1.13[1.00 to 1.27], p = 0.057). Only the prognostic value of uNGAL for ESRD was supported by a grade B level of evidence.
conclusionThe concentration of uNGAL can be used in practice as an independent predictor of end stage renal disease among patients with chronic kidney disease, but it may be not useful in predicting disease progression to CKD stage 3 among community-based population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.